Objective: To assess the effectiveness of cholecalciferol (D3) doses for maintaining adequate vitamin D status in crias and adult female alpacas at pasture.
Design: A field experiment during winter and early spring in a herd on a farm in South Australia. ANIMALS AND PROCEDURE: Crias, usually less than 6 months of age and female alpacas, aged 2 to 6 years, were given a single subcutaneous dose of 0, 1000 or 2000 IU D3/kg body weight. Plasma concentrations of 25-hydroxycholecalciferol (25-OH D3), phosphorus, calcium and vitamins A and E and alkaline phosphatase activity were measured at intervals over a period of 16 weeks after treatment.
Results: Crias not given a vitamin D supplement had reduced growth rate during winter and one animal showed clinical signs of rickets. Vitamin D treatment had no effect on the body weight of mature females. Vitamin D supplements increased the 25-OH D3 and phosphorus concentrations in plasma of both crias and adult females; alkaline phosphatase activity was not affected by treatment.
Conclusion: It is suggested that for alpacas in southern Australia a subcutaneous dose of 1000 IU D3/kg body weight to crias in late autumn and again in mid winter and to adult females in mid winter should prevent vitamin D inadequacy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1751-0813.1999.tb10270.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cardiometabolic index as a predictor of gallstone incidence in U.S. adults: insights from NHANES 2017-2020.
BMC Gastroenterol
January 2025
Department of Nephrology, QingPu Branch of Zhongshan Hospital Affiliated to Fudan University, Shanghai, People's Republic of China.
Background: Gallstone disease (GSD) is associated with obesity. The Cardiometabolic Index (CMI), a metric that accurately assesses central adiposity and visceral fat, has not been extensively studied in relation to GSD risk. This study investigates the link between CMI and GSD incidence in U.
View Article and Find Full Text PDFThe association between 24-h movement behaviours and adiposity among Australian preschoolers: a compositional data analysis.
BMC Public Health
January 2025
Early Start, Faculty of the Arts, Social Sciences and Humanities, University of Wollongong, Wollongong, NSW, 2522, Australia.
Introduction: The relationship between 24-h movement behaviours (i.e. sleep, sedentary behaviour and physical activity) and adiposity in preschoolers remains unclear.
View Article and Find Full Text PDFHow does BMI correlate with menarche onset? Evidence from the Italian HBSC cross-sectional study.
BMC Womens Health
January 2025
Post Graduate School of Public Health, University of Siena, Siena, 53100, Italy.
Menarche is an important period in a female's life; its time of onset may depend on various factors and could correlate with the development of diseases in adulthood. Our study aims to investigate the relationship between body mass index and age at onset of menarche; METHODS: We used a unique standardized national dataset on adolescent girls participating in the Italian Health Behaviour in School-aged Children Study. Two independent nationally representative survey datasets: one on 15-year-olds (n = 6505, year 2017/2018) and one on 11-year-olds (n = 6548, year 2013/2014) were analysed.
View Article and Find Full Text PDFThe association between gestational selective serotonin reuptake inhibitor (SSRI) treatment and newborn thyroid screen: a large-scale cohort study.
BMC Pediatr
January 2025
Institute of Pediatric Endocrinology, Dana Dwek Children's Hospital, Tel Aviv Sourasky Medical Center, 6 Weizmann Street, 6423906, Tel Aviv, Israel.
Background: The diagnosis of depression or anxiety treated by SSRIs has become relatively common in women of childbearing age. However, the impact of gestational SSRI treatment on newborn thyroid function is lacking. We explored the impact of gestational SSRI treatment on newborn thyroid function as measured by the National Newborn Screening (NBS) Program and identified contributory factors.
View Article and Find Full Text PDFOlaparib-induced hyperglycemia in ovarian cancer patients - a case series analysis of a three-month therapy with a consideration of BMI.
Pharmacol Rep
January 2025
Department of Gynaecological Oncology, Poznań University Clinical Hospital, Szamarzewskiego 84, Poznań, Poland.
Background: Olaparib is a relatively new poly(ADP-ribose) polymerase inhibitor (PARPi) administered to ovarian cancer (OC) patients with a complete or partial response to first-line chemotherapy. One of the metabolic side effects of olaparib is the disruption of glucose homeostasis, often resulting in hyperglycemia The study was a retrospective analysis of olaparib-induced hyperglycemia in OC patients with initial normoglycemia following the first, second, and third month of olaparib treatment METHODS: The study involved 32 OC patients, classified into three groups according to their Body Mass Index (BMI): normal BMI (BMI 18.5-24.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!